Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival
Allison Winter(Cleveland Clinic), Brian T. Hill(Cleveland Clinic), Jonathon B. Cohen(Emory University), Timothy Tiutan(NewYork–Presbyterian Hospital), Dhruvika Mukhija(Northwestern University), Mohammad Junaid Hussain(Levine Cancer Institute), Amrita Desai(Oregon Health & Science University), Nathalie Danielson(VA Tennessee Valley Healthcare System), Christopher R. D’Angelo(Susan Thompson Buffett Foundation), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Stefan K. Barta(University of Pennsylvania), Craig A. Portell(University of Virginia), Vaishalee P. Kenkre(University of Wisconsin–Madison), Thomas M. Habermann(Mayo Clinic in Arizona), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Peter Martin(Northwestern University), Izidore S. Lossos(University of Miami), Prathima Reddy(Seattle Cancer Care Alliance), Matthew J. Maurer(Mayo Clinic in Arizona), Pooja Mehra(University of Virginia), Andrew M. Evens(Rutgers, The State University of New Jersey), Alexey V. Danilov(City of Hope), Brad S. Kahl(UW Health University Hospital), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Nilanjan Ghosh(Levine Cancer Institute), James R. Cerhan(Mayo Clinic), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Bita Fakhri(University of California, San Francisco), Brian K. Link(University of Iowa), Abhigna Kodali, Max L. Goldman(Twitter (United States)), Oscar Calzada(Emory University), Stephen D. Smith(Seattle Cancer Care Alliance), Manali Kamdar(University of Colorado Cancer Center), Yang Liu(Fox Chase Cancer Center), Melody Becnel(The University of Texas MD Anderson Cancer Center)
Cited by 10
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k